A phase I trial conducted in 2004 analyzed the effect of i.v. administered rhIL‐12 in combination with the HER2 protein‐binding monoclonal antibody trastuzumab in patients with metastatic HER2‐positive malignancies (breast, n = 12; pancreatic cancer‐2; cervical cancer‐1).27 Here, ERBB2 is linked to cervical cancer.